Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype
, , , , , , , , , and | Sep 08, 2016
About this article
Article Category: Research Article
Published Online: Sep 08, 2016
Page range: 385 - 393
Received: Mar 28, 2016
Accepted: Jun 18, 2016
DOI: https://doi.org/10.1515/raon-2016-0044
© 2016 Radiol Oncol
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Results of sequential studies of IDH+ patients
| Patient ID | Age/ sex | Disease status after induction | Disease status after consolidation therapy | Relapse | ||||
|---|---|---|---|---|---|---|---|---|
| 245 | 53/F | CR | CR | / | yes | / | ||
| 275 | 50/F | CR | CR | yes | ||||
| 280 | 61/F | RD | / | |||||
| / | ||||||||
| 291 | 38/F | RD | / | RD | / | |||
| 305 | 47/M | CR | CR | yes | / | |||
| 320 | 40/M | CR | CR | / | ||||
| 349 | 39/M | CR | / | / | ||||
| 378 | 66/M | ED | / | / | ||||
| 380 | 44/F | CR | yes | |||||
| CR | / | |||||||
| 393 | 54/M | CR | CR | / | yes | / | ||
| 399 | 23/F | ED | / | / | ||||
| 401 | 69/M | RD | / | / | ||||
| 403 | 73/F | RD | / | / | ||||
| 412 | 46/M | RD | / | / | ||||
| 418 | 62/F | CR | CR | / | ||||
| 423 | 43/M | ED | / | / | ||||
| 426 | 56/M | ED | / | / | ||||
| 469 | 63/M | CR | CR | yes | / | |||
| 487 | 73/M | RD | RD | |||||
| 556 | 50/M | ED | / | / | ||||
| 612 | 30/M | CR | CR | / | ||||
| 615 | 40/F | CR | CR | / | ||||
| 645 | 43/F | RD | / | / | ||||
| 672 | 33/F | RD | / | |||||
| 680 | 67/M | ED | / | / |
Clinical characteristics of patients with de novo AML-NK stratified by the presence or absence of IDH mutations
| Parameter | Total (n = 110) | |||
|---|---|---|---|---|
| Male (%) | 62 (56.4) | 13 (21) | 49 (79) | |
| Female (%) | 48 (43.6) | 12 (25) | 36 (75) | |
| 53.5(19-78) | 50(23-73) | 54(19-78) | 0.783 | |
| 0.081 | ||||
| Yes | 45(40.9) | 14(31.1) | 31 (68.9) | |
| No | 65(59.1) | 11(16.9) | 54 (83.1) | |
| Yes | 8(7.3) | 3 (37.5) | 5 (62.5) | |
| No | 102(92.7) | 22(21.6) | 80(78.4) | |
| 16.8 (0.5-195) | 6.9 (0.5-160) | 17.4 (0.8-195) | 0.373 | |
| median, range | 95.5 (6-178) | 100 (57-178) | 94 (6-140) | 0.810 |
| median, range | 68 (1-420) | 109(16-193) | 56 (1-420) | 0.024 |
| 917 (273-7180) | 901 (315-5105) | 922.5 (273-7180) | 0.825 | |
| 26 (0-96) | 60.5 (0-96) | 21 (0-96) | 0.031 | |
| 71 (23-97) | 67 (33-97) | 73 (23-97) | 0.920 | |
| 0.139 | ||||
| M0 | 10 | 4 (40) | 6 (60) | |
| M1 | 22 | 6 (27.3) | 16(72.7) | |
| M2 | 31 | 9 (29) | 22 (71) | |
| M4 | 24 | 5 (21) | 19 (79) | |
| M5 | 22 | 1 (0.05) | 21 (95.5) | |
| M6 | 1 | 0 (0.0) | 1 (100.0) | |
| 0.626 | ||||
| present (%) | 26(23.6) | 5 (19.2) | 21 (80.8) | |
| absent (%) | 84(76.4) | 20 (23.8) | 64 (76.2) | |
| 0.428 | ||||
| present (%) | 9 | 3 (33.3) | 6 (66.7) | |
| absent (%) | 101 | 22 (21.8) | 79 (78.2) | |
| 0.496 | ||||
| present (%) | 42(38.2) | 11(26.2) | 31(73.8) | |
| absent (%) | 68(61.8) | 14(20.6) | 54(79.4) |
Type of IDH1 and IDH2 mutations identified in 110 AML-NK patients
| Mutation | Nucleotide change | Amino acid change | No. of patients |
|---|---|---|---|
| c.394C>T | R132C | 4 | |
| c.395G>A | R132H | 2 | |
| c.394C>G | R132G | 1 | |
| c.394C>A | R132S | 1 | |
| c.419G>A | R140Q | 12 | |
| c.418C>T | R140W | 1 | |
| c.419G>T | R140L | 1 | |
| c.418C>G | R140G | 1 | |
| c.515G>A | R172K | 2 |